Clinical Trials Browser

NIH × Interventional × Lymphoma, Primary Effusion × Clear all

NCT05907759 2026-03-18

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

Phase 2 Recruiting

LymphoidSarcoma

Multi-centric Castleman's Disease, Lymphoma, Non-Hodgkin, Sarcoma, Kaposi, Lymphoma, Primary Effusion

NCT03038672 2025-11-10

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Phase 2 Active not recruiting

54 enrolled 12 charts

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

NCT04975698 2025-10-03

BMTCTN1903

Phase 2 Active not recruiting

Lymphoma, Primary Effusion

NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

Phase 1/2 Active not recruiting

17 enrolled 21 charts

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

NCT01193842 2023-11-21

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

Phase 1/2 Completed

107 enrolled 24 charts

Plasmablastic Lymphoma, Lymphoma, Follicular, HIV Infections, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

NCT02228512 2018-08-31

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Phase 1/2 Withdrawn

Lymphoma, Primary Effusion